Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation
Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved..
BACKGROUND: The relationship between omega-3 fatty acids and atrial fibrillation (AF) remains controversial.
OBJECTIVES: This study aimed to determine the prospective associations of blood or adipose tissue levels of eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA) with incident AF.
METHODS: We used participant-level data from a global consortium of 17 prospective cohort studies, each with baseline data on blood or adipose tissue omega-3 fatty acid levels and AF outcomes. Each participating study conducted a de novo analyses using a prespecified analytical plan with harmonized definitions for exposures, outcome, covariates, and subgroups. Associations were pooled using inverse-variance weighted meta-analysis.
RESULTS: Among 54,799 participants from 17 cohorts, 7,720 incident cases of AF were ascertained after a median 13.3 years of follow-up. In multivariable analysis, EPA levels were not associated with incident AF, HR per interquintile range (ie, the difference between the 90th and 10th percentiles) was 1.00 (95% CI: 0.95-1.05). HRs for higher levels of DPA, DHA, and EPA+DHA, were 0.89 (95% CI: 0.83-0.95), 0.90 (95% CI: 0.85-0.96), and 0.93 (95% CI: 0.87-0.99), respectively.
CONCLUSIONS: In vivo levels of omega-3 fatty acids including EPA, DPA, DHA, and EPA+DHA were not associated with increased risk of incident AF. Our data suggest the safety of habitual dietary intakes of omega-3 fatty acids with respect to AF risk. Coupled with the known benefits of these fatty acids in the prevention of adverse coronary events, our study suggests that current dietary guidelines recommending fish/omega-3 fatty acid consumption can be maintained.
| Errataetall: |
CommentIn: J Am Coll Cardiol. 2023 Jul 25;82(4):350-352. - PMID 37468190 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:82 |
|---|---|
| Enthalten in: |
Journal of the American College of Cardiology - 82(2023), 4 vom: 25. Juli, Seite 336-349 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.07.2023 Date Revised 06.03.2024 published: Print CommentIn: J Am Coll Cardiol. 2023 Jul 25;82(4):350-352. - PMID 37468190 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jacc.2023.05.024 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35968646X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35968646X | ||
| 003 | DE-627 | ||
| 005 | 20240306232336.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacc.2023.05.024 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM35968646X | ||
| 035 | |a (NLM)37468189 | ||
| 035 | |a (PII)S0735-1097(23)05706-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Qian, Frank |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.07.2023 | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: J Am Coll Cardiol. 2023 Jul 25;82(4):350-352. - PMID 37468190 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: The relationship between omega-3 fatty acids and atrial fibrillation (AF) remains controversial | ||
| 520 | |a OBJECTIVES: This study aimed to determine the prospective associations of blood or adipose tissue levels of eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA) with incident AF | ||
| 520 | |a METHODS: We used participant-level data from a global consortium of 17 prospective cohort studies, each with baseline data on blood or adipose tissue omega-3 fatty acid levels and AF outcomes. Each participating study conducted a de novo analyses using a prespecified analytical plan with harmonized definitions for exposures, outcome, covariates, and subgroups. Associations were pooled using inverse-variance weighted meta-analysis | ||
| 520 | |a RESULTS: Among 54,799 participants from 17 cohorts, 7,720 incident cases of AF were ascertained after a median 13.3 years of follow-up. In multivariable analysis, EPA levels were not associated with incident AF, HR per interquintile range (ie, the difference between the 90th and 10th percentiles) was 1.00 (95% CI: 0.95-1.05). HRs for higher levels of DPA, DHA, and EPA+DHA, were 0.89 (95% CI: 0.83-0.95), 0.90 (95% CI: 0.85-0.96), and 0.93 (95% CI: 0.87-0.99), respectively | ||
| 520 | |a CONCLUSIONS: In vivo levels of omega-3 fatty acids including EPA, DPA, DHA, and EPA+DHA were not associated with increased risk of incident AF. Our data suggest the safety of habitual dietary intakes of omega-3 fatty acids with respect to AF risk. Coupled with the known benefits of these fatty acids in the prevention of adverse coronary events, our study suggests that current dietary guidelines recommending fish/omega-3 fatty acid consumption can be maintained | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a docosahexaenoic acid | |
| 650 | 4 | |a docosapentaenoic acid | |
| 650 | 4 | |a eicosapentaenoic acid | |
| 650 | 4 | |a observational epidemiology | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Docosahexaenoic Acids |2 NLM | |
| 650 | 7 | |a 25167-62-8 |2 NLM | |
| 650 | 7 | |a Eicosapentaenoic Acid |2 NLM | |
| 650 | 7 | |a AAN7QOV9EA |2 NLM | |
| 650 | 7 | |a Fatty Acids, Omega-3 |2 NLM | |
| 700 | 1 | |a Tintle, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Jensen, Paul N |e verfasserin |4 aut | |
| 700 | 1 | |a Lemaitre, Rozenn N |e verfasserin |4 aut | |
| 700 | 1 | |a Imamura, Fumiaki |e verfasserin |4 aut | |
| 700 | 1 | |a Feldreich, Tobias Rudholm |e verfasserin |4 aut | |
| 700 | 1 | |a Nomura, Sarah Oppeneer |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Weihua |e verfasserin |4 aut | |
| 700 | 1 | |a Laguzzi, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Eunjung |e verfasserin |4 aut | |
| 700 | 1 | |a Virtanen, Jyrki K |e verfasserin |4 aut | |
| 700 | 1 | |a Steur, Marinka |e verfasserin |4 aut | |
| 700 | 1 | |a Bork, Christian S |e verfasserin |4 aut | |
| 700 | 1 | |a Hirakawa, Yoichiro |e verfasserin |4 aut | |
| 700 | 1 | |a O'Donoghue, Michelle L |e verfasserin |4 aut | |
| 700 | 1 | |a Sala-Vila, Aleix |e verfasserin |4 aut | |
| 700 | 1 | |a Ardisson Korat, Andres V |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Rimm, Eric B |e verfasserin |4 aut | |
| 700 | 1 | |a Psaty, Bruce M |e verfasserin |4 aut | |
| 700 | 1 | |a Heckbert, Susan R |e verfasserin |4 aut | |
| 700 | 1 | |a Forouhi, Nita G |e verfasserin |4 aut | |
| 700 | 1 | |a Wareham, Nicholas J |e verfasserin |4 aut | |
| 700 | 1 | |a Marklund, Matti |e verfasserin |4 aut | |
| 700 | 1 | |a Risérus, Ulf |e verfasserin |4 aut | |
| 700 | 1 | |a Lind, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Ärnlöv, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Garg, Parveen |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Michael Y |e verfasserin |4 aut | |
| 700 | 1 | |a Pankow, James |e verfasserin |4 aut | |
| 700 | 1 | |a Misialek, Jeffrey R |e verfasserin |4 aut | |
| 700 | 1 | |a Gigante, Bruna |e verfasserin |4 aut | |
| 700 | 1 | |a Leander, Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Pester, Julie A |e verfasserin |4 aut | |
| 700 | 1 | |a Albert, Christine M |e verfasserin |4 aut | |
| 700 | 1 | |a Kavousi, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Ikram, Arfan |e verfasserin |4 aut | |
| 700 | 1 | |a Voortman, Trudy |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt, Erik B |e verfasserin |4 aut | |
| 700 | 1 | |a Ninomiya, Toshiharu |e verfasserin |4 aut | |
| 700 | 1 | |a Morrow, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Bayés-Genís, Antoni |e verfasserin |4 aut | |
| 700 | 1 | |a O'Keefe, James H |e verfasserin |4 aut | |
| 700 | 1 | |a Ong, Kwok Leung |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jason H Y |e verfasserin |4 aut | |
| 700 | 1 | |a Mozaffarian, Dariush |e verfasserin |4 aut | |
| 700 | 1 | |a Harris, William S |e verfasserin |4 aut | |
| 700 | 1 | |a Siscovick, David S |e verfasserin |4 aut | |
| 700 | 0 | |a Fatty Acids and Outcomes Research Consortium (FORCE) |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American College of Cardiology |d 1987 |g 82(2023), 4 vom: 25. Juli, Seite 336-349 |w (DE-627)NLM012608602 |x 1558-3597 |7 nnns |
| 773 | 1 | 8 | |g volume:82 |g year:2023 |g number:4 |g day:25 |g month:07 |g pages:336-349 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jacc.2023.05.024 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 82 |j 2023 |e 4 |b 25 |c 07 |h 336-349 | ||